Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: A systematic review and meta-analysis

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 11, 2015, Pages 886-894

  Pittas, Anastassios G ^a   Westcott, Gregory P ^a   Balk, Ethan M ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ANTIDIABETIC AGENT;

ARTICLE; BODY MASS; BODY WEIGHT DISORDER; COUGHING; DIABETIC PATIENT; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ACCEPTABILITY; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN; ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRY POWDER INHALER; FEMALE; MALE; MIDDLE AGED; PHARMACEUTICS; REGISTER; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRY POWDER INHALERS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84955691745     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00280-6     Document Type: Article

References (43)

1. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med 2014; 160: 517-25.
2. Peyrot M, Rubin RR, Lauritzen T, et al, for the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28: 2673-79.
3. Holmes-Truscott E, Skinner TC, Pouwer F, Speight J. Negative appraisals of insulin therapy are common among adults with type 2 diabetes using insulin: results from Diabetes MILES-Australia cross-sectional survey. Diabet Med 2015; published online Feb 13. DOI:10.1111/dme.12729.
4. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145: 665-75.
5. FDA. Drug Safety Labeling Changes. Exubera (insulin human [rDNA origin]) Inhalation Powder September 2008. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm122978.htm (accessed Aug 17, 2015).
6. FDA. FDA approves Afrezza to treat diabetes, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm (accessed June 10, 2015).
7. Sanofi.Sanofi and MannKind announce Afrezza. http://en.sanofi.com/Images/38264_20150203_Afrezza_en.pdf (accessed June 10, 2015).
8. Pfützner A, Forst T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005; 2: 1097-106.
9. Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009; 11: 715-20.
10. MannKind Corporation. Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Afrezza (Technosphere Insulin Inhalation System). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm390865.pdf (accessed Oct 1, 2014).
11. Briefing Document FDA. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Afrezza (Technosphere insulin inhalation system). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390864.pdf (accessed Oct 1, 2014).
12. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27: 1761-73.
13. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010; 375: 2244-53.
14. Higgins JP, Altman DG, Gøtzsche PC, et al,. for the Cochrane Bias Methods Group, and the Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
15. Stack CB, Localio AR, Griswold ME, Goodman SN, Mulrow CD. Handling of rescue and missing data aff ects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example. Ann Intern Med 2013; 159: 285-88.
16. Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random eff ects. Stat Med 1996; 15: 619-29.
17. Trikalinos TA, Trow P, Schmid CH. Simulation-based comparison of methods for meta-analysis of proportions and rates. Agency for Healthcare Research and Quality (US): Rockville, USA, 2013.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
19. Study MKC-TI-101. A 3 month, randomized, open label, multicenter study of technosphere/insulin compared to insulin aspart in subjects with type 1 diabetes mellitus receiving insulin glargine. ClinicalTrials.gov identifier NCT00539396. https://clinicaltrials.gov/ct2/show/NCT00539396 (accessed May 30, 2015).
20. Study MKC-TI-117. Safety and efficacy of technosphere® insulin inhalation powder and lantus® compared to Humalog® and Lantus® over 16-weeks. ClinicalTrials.gov identifier NCT00700622. https://clinicaltrials.gov/ct2/show/NCT00700622 (accessed May 30, 2015).
21. Study MKC-TI-171. A phase 3, multicenter, open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of technosphere insulin inhalation powder in combination with a basal insulin versus insulin aspart in combination with a basal insulin in subjects with type 1 diabetes mellitus over a 24-week treatment period. ClinicalTrials.gov identifier NCT01445951. https://clinicaltrials.gov/ct2/show/NCT01445951 (accessed May 30, 2015).
22. Study MKC-TI-009. Efficacy and safety of inhaled insulin in type 1 diabetes. ClinicalTrials.gov identifier NCT00308308. https://clinicaltrials.gov/ct2/show/NCT00308308 (accessed May 30, 2015).
23. Tack CJ, Christov V, de Galan BE, et al, and the 005 Study Group. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2: 47-57.
24. Study MKC-TI-162. Clinical trial evaluating the efficacy and safety of technosphere® inhalation insulin (ti) inhalation powder using the Gen2 inhaler. ClinicalTrials.gov identifier NCT01196104. https://clinicaltrials.gov/ct2/show/NCT01196104 (accessed May 30, 2015).
25. Study MKC-TI-014. Comparison between Technosphere/insulin inhalation powder versus rapid acting insulin in subjects with type diabetes mellitus. ClinicalTrials.gov identifier NCT00539890. https://clinicaltrials.gov/ct2/show/NCT00539890 (accessed May 30, 2015).
26. Rosenstock J, Bergenstal R, Defronzo RA, et al, and the 0008 Study Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008; 31: 2177-82.
27. Study MKC-TI-103. Efficacy and safety of prandial inhalation of technosphere/insulin in combination with metformin or technosphere/insulin alone versus 2 oral anti-diabetic agents in subjects with type 2 diabetes. ClinicalTrials.gov identifier: NCT00332488. https://clinicaltrials.gov/ct2/show/NCT00332488 (accessed May 30, 2015).
28. Study MKC-TI-175. A phase 3, multicenter, double-blind, placebocontrolled, randomized, clinical trial evaluating the efficacy and safety of prandial technosphere insulin inhalation powder versus technosphere inhalation powder (placebo) in insulin-naïve subjects with type 2 diabetes mellitus poorly controlled with oral antidiabetic agents over a 24-week treatment period. ClinicalTrials.gov identifier NCT01451398. https://clinicaltrials.gov/ct2/show/NCT01451398 (accessed May 30, 2015).
29. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2. years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab 2012; 14: 163-73.
30. Study MKC-TI-010. An open-label, multi-center, international, three-year, safety and tolerability 'follow on' trial. ClinicalTrials.gov identifier NCT00754624. https://clinicaltrials.gov/ct2/show/NCT00754624 (accessed May 30, 2015).
31. Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther 2011; 13: 1201-06.
32. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
33. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
34. MKC-TI-176 S. Healthy normal volunteers looking at exposure and eff ects of multiple doses of Technosphere® insulin (TI) using the Gen2C inhaler. ClinicalTrials.gov identifier NCT01490762.
35. Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH. How to use a noninferiority trial: users' guides to the medical literature. JAMA 2012; 308: 2605-11.
36. A2171121. An observational follow-up study of patients previously enrolled in exubera controlled clinical trials. ClinicalTrials.gov identifier NCT00734591.
37. Petrucci R, Amin N, Lovertin P, Boss A, Richardson P. Pulmonary function tests remain similar in patients who received Technosphere insulin and in patients currently receiving standard anti-diabetic therapy. Diabetologia 2009; 52 (suppl 1): S361 (abstr 919).
38. Potocka E, Cassidy JP, Haworth P, Heuman D, van Marle S, Baughman RA Jr. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Tech 2010; 4: 1164-73.
39. Pfützner A, Mann AE, Steiner SS. Technosphere/Insulin-a new approach for eff ective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4: 589-94.
40. Cassidy JP, Marino MT, Amin N. Lung deposition and absorption of insulin from AFRESA (Technosphere insulin). American Diabetes Association 69th Scientifi c Sessions. New Orleans, LA, USA; June 5-9, 2009; 433-P (abstr).
41. Brain J, Finch GL, Rice RJ, Schwartz PF, Teeter JG. Trough insulin levels in bronchoalveolar lavage following inhaltion of human insulin (Exubera) in patients with diabetes mellitus. America Thoracic Society Annual Meeting. Toronto, ON, Canada; May 16-21, 2008; 616 (abstr).
42. Sanofi-Aventis. Afrezza: risk evaluation and mitigation strategy. http://www.accessdata.fda.gov/drugsatfda_docs/rems/Afrezza_2015.04.20_REMS_document.pdf (accessed Aug 17, 2015).
43. Godlee F. Goodbye PubMed, hello raw data. BMJ 2011; 342: d212.